Taiwan says Thailand prioritising AstraZeneca shots for itself



TAIPEI, June 11 (Reuters) - Thailand is prioritising for itself AstraZeneca Plc's AZN.L COVID-19 vaccines produced in the southeast Asian nation because of the severity of the pandemic there, thus delaying deliveries to Taiwan, President Tsai Ing-wen said on Friday.

The island is battling a spike in domestic infections and just 3% of its 23.5 million people have received at least one vaccine dose, with millions of shots on order but yet to arrive.

"The problem is that the goods that were supposed to have arrived in June have not," Tsai told a Taiwan radio station.

Taiwan has ordered 10 million doses from AstraZeneca, which is mainly producing them in Thailand, she added.

"Now Thailand's epidemic situation is serious and they are giving priority for vaccines to be used in Thailand."

Thailand has reported 189,828 infections, with more than 80% of the new figures recorded since April.

Neither AstraZeneca nor Thai government officials immediately responded to requests for comment.

On Tuesday, Taiwan's Health Minister Chen Shih-chung had told lawmakers that production problems at AstraZeneca's Thai plant would delay supplies by a month.

Taiwan received 1.24 million AstraZeneca doses donated by Japan last week, and the United States has pledged 750,000 shots, but there are no details of the latter.

Tsai said the government had been having "emergency" talks with the United States and Japan to see what other vaccines they might be able to provide.

Tsai has come under pressure to do more to speed up vaccine deliveries, and speaking later on Tuesday expressed apologies for the infections and deaths.

"The government team will definitely make every effort to control the epidemic," she said in a broadcast from her office.

Chen told parliament that government-run research centre Academia Sinica had made good progress on mRNA technology and had contacted Moderna Inc MRNA.O about working with it on vaccines.

Moderna did not immediately respond to a request for comment.

Taiwan has received just 150,000 Moderna doses of more than 5 million on order.



Interactive graphic on vaccine roll-out: Link
FACTBOX-Worldwide coronavirus deaths exceed 3.9 mln

ID:nL4N2AY3AS FACTBOX-Latest on global spread of coronavirus

ID:nL8N2AB5TN



Reporting by Yimou Lee and Ben Blanchard; Additional reporting by Chayut Setboonsarng in Bangkok; Editing by Lincoln Feast and Clarence Fernandez

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.